Private Equity
Available capital and promise of consumer staples keep sponsors around but most companies will not seal deals in the near term.
3 min read · 24 March 2020
While many traditional PE shops are busy assessing the potential impacts of covid-19 on their portfolios, a few are turning to their companies to develop vaccines and tests to curb the spread of coronavirus.
4 min read · 24 March 2020
Amid the COVID-9 crisis, some firms are invoking the MAC clause to pull out of deals.
3 min read · 24 March 2020
The turnaround expert shares his take on covid-19's impact on PE, asserting that he's seeing MAC clauses implemented for the first time in his 20-year career.
6 min read · 23 March 2020
Areas of the healthcare industry will likely be triggered into action, spurring innovation, as bottlenecks in the system become increasingly clear amid covid-19, says the venture and growth-equity investor.
3 min read · 23 March 2020
This week’s jobs include a principal at Wellington and associates at Lazard and Rothschild.
2 min read · 23 March 2020
Thoma Bravo calls off its potential $2 billion-plus sale of Imprivata amid the coronavirus pandemic and New York State Common Retirement Fund commits to a $2 billion co-investment fund with Neuberger Berman.
3 min read · 23 March 2020
Imprivata, which helps healthcare providers protect patient information, was anticipated to command upwards of $2bn in a potential sale.
2 min read · 20 March 2020
Are private asset classes better positioned to weather the crisis? Our senior editorial teams covering PE, private debt, infrastructure, real estate and secondaries provide insight.
1 min read · 20 March 2020
MiddleGround is paying leave for employees who test positive for COVID-19 and trying to de-stress during a period of excessive stress.
4 min read · 20 March 2020
